Recruitment

Recruitment Status
Completed
Estimated Enrollment
24

Inclusion Criterias

Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant's well being
Positive skin prick test to at least one common aeroallergen
Male or female 18-70 years
...
Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant's well being
Positive skin prick test to at least one common aeroallergen
Male or female 18-70 years
Able to comply with the requirements of the protocol
Able to provide informed consent
Diagnosis of allergic rhinitis
Peak nasal inspiratory flow which is reversible to >20 l/min with oxymetazoline
Ability to withhold antihistamines, intranasal corticosteroids for duration of the study

Exclusion Criterias

Other cardiovascular medications including but not limited to:
Any known adverse reaction to the Investigational Medicinal Product or other quinazolines
Participation within another clinical trial of investigational medicinal product within the last 30 days
...
Other cardiovascular medications including but not limited to:
Any known adverse reaction to the Investigational Medicinal Product or other quinazolines
Participation within another clinical trial of investigational medicinal product within the last 30 days
Any degree of heart block
History of oesophageal or gastrointestinal obstruction or decreased lumen diameter of the gastrointestinal tract.
Any clinically significant medical condition that may endanger the health or safety of the participant or jeopardise the protocol
Pregnancy, planned pregnancy or lactation
Systolic BP <100mmHg
Benign hyperplasia, chronic urinary tract infections, bladder stones, overflow bladder, anuria or progressive renal failure
Nasal polyps of more than Grade I on nasal endoscopy
Under the age of 18
Alpha antagonists - this is the medication under investigation.
Respiratory tract infection in the previous 2 months
Concomitant use of PDE5 inhibitors (sildenafil etc.)

Summary

Conditions
Allergic Rhinitis
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: Triple (Participant, Care Provider, Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 70 years
Gender
Both males and females

Inclusion Criterias

Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant's well being
Positive skin prick test to at least one common aeroallergen
Male or female 18-70 years
...
Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant's well being
Positive skin prick test to at least one common aeroallergen
Male or female 18-70 years
Able to comply with the requirements of the protocol
Able to provide informed consent
Diagnosis of allergic rhinitis
Peak nasal inspiratory flow which is reversible to >20 l/min with oxymetazoline
Ability to withhold antihistamines, intranasal corticosteroids for duration of the study

Exclusion Criterias

Other cardiovascular medications including but not limited to:
Any known adverse reaction to the Investigational Medicinal Product or other quinazolines
Participation within another clinical trial of investigational medicinal product within the last 30 days
...
Other cardiovascular medications including but not limited to:
Any known adverse reaction to the Investigational Medicinal Product or other quinazolines
Participation within another clinical trial of investigational medicinal product within the last 30 days
Any degree of heart block
History of oesophageal or gastrointestinal obstruction or decreased lumen diameter of the gastrointestinal tract.
Any clinically significant medical condition that may endanger the health or safety of the participant or jeopardise the protocol
Pregnancy, planned pregnancy or lactation
Systolic BP <100mmHg
Benign hyperplasia, chronic urinary tract infections, bladder stones, overflow bladder, anuria or progressive renal failure
Nasal polyps of more than Grade I on nasal endoscopy
Under the age of 18
Alpha antagonists - this is the medication under investigation.
Respiratory tract infection in the previous 2 months
Concomitant use of PDE5 inhibitors (sildenafil etc.)

Locations

Dundee, DD1 3AU
Dundee, DD1 3AU

Tracking Information

NCT #
NCT01946035
Collaborators
Not Provided
Investigators
  • Principal Investigator: Brian J Lipworth, MD University of Dundee Principal Investigator: Arvind Manoharan, MBChB University of Dundee
  • Brian J Lipworth, MD University of Dundee Principal Investigator: Arvind Manoharan, MBChB University of Dundee